{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:42:17Z","timestamp":1794271337832,"version":"4.9.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3501304"],"award-info":[{"award-number":["2022YFC3501304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201492"],"award-info":[{"award-number":["82201492"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271378"],"award-info":[{"award-number":["82271378"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.neurot.2025.e00730","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T15:23:00Z","timestamp":1757085780000},"page":"e00730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study"],"prefix":"10.1016","volume":"22","author":[{"given":"Rongjing","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neurot.2025.e00730_bib1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00730_bib2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3389\/fneur.2020.00604","article-title":"A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature","volume":"11","author":"Farrugia","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2025.e00730_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00730_bib4","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","article-title":"Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases","volume":"94","author":"Neumann","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00730_bib5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00730_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.767961","article-title":"Patients with Myasthenia gravis with acute onset of dyspnea: predictors of progression to myasthenic crisis and prognosis","volume":"12","author":"Huang","year":"2021","journal-title":"Front Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00730_bib7","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/mus.27922","article-title":"Updated consensus statement: intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee","volume":"68","author":"Tavee","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurot.2025.e00730_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1196\/annals.1405.001","article-title":"Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin","volume":"1132","author":"Gajdos","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00730_bib9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMp2403596","article-title":"Ensuring a safe and sufficient global blood supply","volume":"391","author":"Jacobs","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00730_bib10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14737175.2022.2057223","article-title":"Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis","volume":"22","author":"Dalakas","year":"2022","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00730_bib11","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Investig"},{"issue":"23","key":"10.1016\/j.neurot.2025.e00730_bib12","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00730_bib13","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00730_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16098","article-title":"Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study","volume":"31","author":"Bril","year":"2024","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurot.2025.e00730_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578431","article-title":"Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: a single-center case series","volume":"395","author":"Hong","year":"2024","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00730_bib16","article-title":"Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis","volume":"14","author":"Ma","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2025.e00730_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241254895","article-title":"Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report","volume":"17","author":"Zhang","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2025.e00730_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1418503","article-title":"Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series","volume":"15","author":"Song","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00730_bib19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/CND.0000000000000156","article-title":"Outcome measures in Myasthenia Gravis: incorporation into clinical practice","volume":"18","author":"Muppidi","year":"2017","journal-title":"J Clin Neuromuscul Dis"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00730_bib20","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00730_bib21","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1007\/s00415-022-11517-w","article-title":"Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)","volume":"270","author":"Sacca","year":"2023","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00730_bib22","article-title":"Exacerbation of Thymoma-Associated Myasthenia gravis following efgartigimod treatment related to anti-acetylcholine receptor antibody overshoot: a report of two cases","volume":"15","author":"Kawama","year":"2023","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00730_bib23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mus.27341","article-title":"Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis","volume":"64","author":"Ching","year":"2021","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00730_bib24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jca.22036","article-title":"Failure of double filtration plasmapheresis to treat severe pemphigus vulgaris: a case report","volume":"38","author":"Liu","year":"2023","journal-title":"J Clin Apher"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00730_bib25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/trf.12923","article-title":"Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients","volume":"55","author":"Yamada","year":"2015","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00730_bib26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/jca.2920100410","article-title":"Immunologic rebound","volume":"10","author":"Dau","year":"1995","journal-title":"J Clin Apher"},{"key":"10.1016\/j.neurot.2025.e00730_bib27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/ITT.S261414","article-title":"Complement inhibition for the treatment of Myasthenia gravis","volume":"9","author":"Mantegazza","year":"2020","journal-title":"ImmunoTargets Ther"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00730_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmrv.2023.150767","article-title":"Therapeutic plasma exchange versus FcRn inhibition in autoimmune disease","volume":"38","author":"Mina-Osorio","year":"2024","journal-title":"Transfus Med Rev"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:29:15Z","timestamp":1763638155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925002089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1878747925002089"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00730","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00730","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00730"}}